Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Descending) Package Effective Date Package Discontinuation Date Status
54868-5260-05 54868-5260 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral June 28, 2005 In Use
54868-5260-09 54868-5260 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral June 28, 2005 In Use
55111-0496-05 55111-0496 capecitabine capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 10, 2020 In Use
55111-0496-60 55111-0496 capecitabine capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 10, 2020 In Use
55111-0497-04 55111-0497 capecitabine capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 10, 2020 In Use
55111-0497-05 55111-0497 capecitabine capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 10, 2020 In Use
59572-0730-07 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 18, 2020 In Use
59572-0730-14 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2020 In Use
59572-0740-07 59572-0740 azacitidine ONUREG 300.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 18, 2020 In Use
59572-0740-14 59572-0740 azacitidine ONUREG 300.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2020 In Use
59651-0240-90 59651-0240 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral July 23, 2020 In Use
59651-0241-03 59651-0241 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral July 23, 2020 In Use
59651-0241-30 59651-0241 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral July 23, 2020 In Use
59923-0723-90 59923-0723 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 1, 2020 In Use
59923-0724-30 59923-0724 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 1, 2020 In Use
62756-0238-18 62756-0238 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0238-86 62756-0238 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0238-88 62756-0238 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0239-18 62756-0239 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0239-20 62756-0239 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0239-83 62756-0239 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
63020-0536-30 63020-0536 ponatinib hydrochloride Iclusig 10.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 11, 2021 In Use
63304-0095-11 63304-0095 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0095-30 63304-0095 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0096-11 63304-0096 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use

Found 10,000 results in 3 milliseconds — Export these results